natgillin/translations-raw huggingface dataset:
The composition of claim 1, wherein the functional nucleic acid molecule targets the transcript of MRP2, BCR-ABL, STI-571 resistance-associated protein, lung resistance-related protein, cyclooxygenase-2, nuclear factor kappa, XRCC1, ERCC1, GSTP1, mutant B-tubulin, vascular endothelial growth factor (VEGF), insulin like growth factor (IGF), or hepatocyte growth factor/scatter factor (HGF/SF or SF/HGF). 
Sastav zahtjeva 3, time naznačeno da je protein MRP2, BCR-ABL, STI-571 povezan sa stvaranjem otpornosti, LRP (lung resistance related protein), ciklooksigenaza-2, nuklearni čimbenik kapa, XRCC1, ERCC1, GSTP1, mutant B-tubulin ili čimbenik rasta.
a de-puncturing means configured to perform de-puncturing on LDPC parity bits; an LDPC decoder configured to LDPC-decode the L1 signaling data and the depunctured LDPC parity bits; and 
Prijamnik iz patentnog zahtjeva 7, pri čemu prvi FEC dekoder obuhvaća: sredstvo zatvaranja probijanja konfigurirano za zatvaranje probijanja na LDPC paritetnim bitovima;
The portable cooking and delivery system of claim 6, further comprising: 
Prenosivi sustav za kuhanje i dostavu prema zahtjevu 6, naznačen time, da nadalje obuhvaća sljedeće:
is hydrogen, unsubstituted alkyl, unsubstituted alkenyl or unsubstituted alkynyl; or R8 and R9 in combination form oxo or oxime; and each of R10 is independently selected from the group consisting of hydrogen, fluoro, chloro, hydroxy, and unsubstituted-alkyl; or two R10 and the carbon atom(s) they are attached to form a 3- to 8-membered unsubstituted cycloalkyl or unsubstituted heterocycloalkyl. 
Ro je vodik, nesupstituirani alkil, nesupstituirani alkenil ili nesupstituirani alkinil; ili Rz 1 Ry zajedno tvore okso ili oksim; i svaki od Ryo je neovisno odabran iz skupine koja se sastoji od vodika, fluora, klora, hidroksi i nesupstituiranog alkila; ili dva Ryo i ugljikov(i) atom(i) na koje su oni priključeni, tvore 3-člani do 8-člani nesupstituirani cikloalkila ili nesupstituirani heterocikloalkil.
• a human antibody. 
* ljudsko protutijelo.
Vaccine formulation comprising a peptide consisting of SEQ ID No. 137 or variants thereof comprising a conservative amino acid substitution. 
Formulacija cjepiva, naznačena time, da obuhvaća peptid koji se sastoji od SEQ ID NO:52.
This has been observed in many common human cancers (reviewed in Klapper et al., Adv. Cancer Res., 2000, 77, 25) such as breast cancer (Sainsbury et al., Brit. 
Ovo je primijećeno u velikom broju uobičajenih humanih tumota (pregledano u Klapper i sur., Adv. Cancer Res., 2000, 77, 25), npr. raku dojke (Sainsbury i sur., Brit.
An antisense oligonucleotide of any one of claim 1-4, or a composition of claim 5, for use in a method of treatment of muscular dystrophy. 
Antisens oligonukleotid u skladu s bilo kojim od patentnih zahtjeva 1 do 17 ili pripravak u skladu s patentnim zahtjevom 18, naznačen time što je namijenjen upotrebi u postupku liječenja mišićne distrofije kod pacijenta.
In certain embodiments the hydrogen donor is a heterocycle, optionally substituted with one or more substituents Q. In certain embodiments the hydrogen donor is dihydrofuran. In certain embodiments, the hydrogen donor is diazene, hydrazine, hydroxylamine, or NaH2PO2. In certain embodiments, the hydrogen donor is methanol, ethanol, propan-1-ol, propan-2-ol, butan-1-ol, butan-2-ol, cyclopentanol, cyclohexanol, benzylalcohol, a menthol, formic acid, lactic acid, ascorbic acid, mandelic acid, ammonium formate, potassium formate, cyclohexadiene, cyclohexene, 1-methylcyclohexene, tetralin, dihydrofuran, a terpene, diazene, hydrazine, hydroxylamine, or NaH2PO2, or a mixture thereof. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što je donor vodika metanol, etanol, propan-1-ol, propan-2-ol, butan-1-ol, butan-2-ol, ciklopentanol, cikloheksanol, benzilalkohol, mentol, mravlja kiselina, mliječna kiselina, askorbinska kiselina, bademova Kiselina, amonijev formijat, kalijev formijat, cikloheksadien, cikloheksen, 1-metilcikloheksen, tetralin, dihidrofuran, terpen, diazen, hidrazin, hidroksilamin ili NaH2PO2, ili njihova smjesa; ili gdje je donor vodika mravlja kiselina, amonijev formijat, kalijev formijat, cikloheksen, 1-metilcikloheksen, NaH2P02, ili njihova smjesa; ili gdje je donor vodika C1-14 karboksilna kiselina.
characterized by a mutant JAK2 wherein at least one mutation of said mutant JAK2 resides in the pseudo-kinase domain of said JAK2 
Spoj ili sol prema zahtjevu 67 naznačen time da barem jedna mutacija navedene mutirane JAK2 nalazi se u domeni pseudo-kinaze navedene JAK2.
Examples of bases capable of releasing the cation An+, and examples of reaction conditions are given below. 
Primjeri lužina sposobnih da oslobode kation A"" i primjeri reakcijskih uvjeta dani su niže.
Example 5 Hydrothermal Synthesis of Tetragonal Nano-sized Zirconia 
Primjer 5 - Hidrotermalna sinteza tetragonskog cirkonijevog okside nano-veličina
The UVR indicator according to claim 10 wherein the altered characteristics of said first and second UVB and/or UVA radiation sensitive materials combine to provide a visual indication of degree of UVB and/or UVA dose over time. The UVR indicator according to claim 11 wherein the second prompt UVB and/or UVA radiation sensitive material may change colour in response to a first initial dose/level of UVB and/or UVA radiation and the first delayed UVB and/or UVA radiation sensitive material may change colour in response to an increased dose of UVB and/or UVA radiation. 
Indikator UV zračenja prema bilo kojem od zahtjeva 3 - 8 naznačen time da se promijenjena karakteristika navedenog prvog i drugog materijala koj1 su osjetljivi na UVB 1/1li UVA zračenje kombinira da se dobije vizualni pokazatelj stupnja UVB i/ili UVA doze, obično tijekom vremena, i proizvoljno pri čemu su promijenjene karakteristike prvog i drugog materijala koji su osjetljivi na UVB i/ili UVA zračenje međusobno opazive, i proizvoljno pri čemu promijenjena karakteristika je promjena boje.
at least one pump boosting LNG pressure; 
- < najmanje jednu crpku (A1, A2) koja pojačava tlak ukapljeni prirodni plin;
In embodiments of the invention of formula I, Ar is selected from the group consisting of phenyl, substituted phenyl, thiophen-yl, substituted thiophen-yl, pyridinyl, substituted pyridinyl, thiazolyl, substituted thiazolyl, pyrimidinyl, substituted pyrimidinyl, furanyl, substituted furanyl, bicyclic aryl, substituted bicyclic aryl, bicyclic heteroaryl, and substituted bicyclic heteroaryl; 
Ar je odabran iz skupine koju čine: fenil, supstituirani fenil, tiofen-il, supstituirani tiofen-il, piridinil, supstituirani piridinil, tiazolil, supstituirani tiazolil, pirimidinil, supstituirani pirimidinil, furanil, supstituirani furanil, biciklički aril, supstituirani biciklički aril, biciklički heteroaril i supstituirani biciklički heteroaril;
The compound of claim 1, wherein R2 is sulfamoylphenyl. The compound of claim 7, wherein R2 is 4-sulfamoylphenyl. 
Tvar iz patentnog zahtjeva 1 ili patentnog zahtejva 2, pri čemu je R2 4-sulfamoilfenil.
Suitably a mixture of pigments may comprise a mixture of the pigments: white 6 (typically titanium dioxide), black 7 (typically carbon black), green 7 (typically copper phthalocyanine CAS No. 
Na prikladan način može mješavina pigmenata sadržavati mješavinu sljedećih pigmenata: bijeli 6 (tipično titanov dioksid), crni 7 (tipično crni ugljen), zeleni 7 (tipično bakreni ftalocianin CAS br.
The process according to claim 6, characterized in that heat treatment of the feed mixture, which contains the fatty acid mixture, is carried out in an expander, preferably in the presence of an emulsifier. 
Postupak prema zahtjevu 6, naznačeno time da je toplinska obrada mješavine životinjske hrane, koja sadrži mješavinu masnih kiselina, izvedena u ekspanderu, poželjno u prisutnosti emulgatora.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the extended release matrix formulation after having been stored at 25°C and 60 % relative humidity (RH), preferably at 40°C and 75 % relative humidity (RH), for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25°C i 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37°C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1, 4 i 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
The pharmaceutical composition according to any of claims 1 - 6, wherein the pharmaceutical composition provides a mean drug exposure and AUC0-24hr from about 18.00 µg·hr/ml to about 22.00 µghr/ml, based on administration of a 2000 mg once-a-day dose of metformin. 
Farmaceutski sastav sukladno bilo kojem od zahtjeva 1 - 6, pri čemu farmaceutski sastav osigurava srednje izlaganje lijeku i AUC9.24p od oko 18.00 ug-h/ml do oko 22.00 ug:h/ml, na osnovi primjene 2000 mg metformina u jednoj dozi dnevno.
By chlorination of the Compound of Example 4 
Broj objave europskog patenta:
However, since in most cases of abuse it is still necessary to pulverise the dosage form comprising an active ingredient suitable for abuse, it was the object of the present invention to complicate or prevent the pulverisation preceding abuse of the dosage form comprising the agents conventionally available for potential abuse and accordingly to provide a dosage form for active ingredients with abuse potential which ensures the desired therapeutic effect when correctly administered, but from which the active ingredients cannot be converted into a form suitable for abuse simply by pulverisation. SUMMARY OF THE INVENTION 
Budući da je u većini slučajeva za zlouporabu potrebno pulveriziranje oblika davanja koji sadrži tvari prikladne za zlouporabu, zadaća ovog izuma bila je da se pulveriziranje oblika davanja koje prethodi zlouporabi oteža, odnosno spriječi sredstvima koja uobičajeno stoje na raspolaganju potencijalnom zlorabitelju i time stavi na raspolaganje kruti oblik davanja djelatnih tvari s potencijalom za zlouporabu, koji kod propisane aplikacije jamči željeno terapeutsko djelovanje, iz kojeg se oblika međutim djelatne tvari ne mogu jednostavnim pulveriziranjem prevesti u oblik koji je prikladan za zlouporabu.
Method according to any one of embodiments 7-9, wherein the scratch resistant particles are or comprise disc shaped particles, preferably having a width/thickness ratio being equal or exceeding 3:1, more preferably being equal or exceeding 5:1. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da čestice otporne na ogrebotine jesu ili sadrže čestice od silicijevog dioksida u obliku diska, koje imaju omjer širine/debljine veći ili jednak od 3:1, poželjnije veći ili jednak od 5:1.
t is an integer from 1 to 10 and can also be 0, 
* ujecijeli broj od 1 do 10, a također može biti i 0;
(0-2) reacting the compound of formula I' with a compound of formula III to obtain a compound of formula IV' wherein X is as defined above, and (0-3) substituting X with PLG by reaction of a reagent PLG-H in the presence of a base, to obtain a compound of formula VI' or 
gdje X je Clili Br, (0-2) reakcija spoja formule I' sa spojem formule III kako bi se dobio spoj formule IV' gdje je X isti kao što je gore definiran, i (0-3) supstitucija X s PLG pomoću reakcije reagensa PLG-H u prisutnosti baze,
Treatment of pyrroloquinoline XIX with differently substituted aryl sulfonyl halide, arylacyl halide or arylalkyl halide derivatives in the presence of a strong base or phosphazene bases to yield the final products XIV, in case of the Boc-protected amines the final products were deprotected in acidic conditions. 
obrade pirolokinolina XIX različito supstituiranim aril-sulfonil-halogenidnim, arilacil-halogenidnim ili arilalkil-halogenidnim derivatima, u prisutnosti jake baze ili fosfazenskih baza, kako bi se dobilo konačne produkte XIV, gdje se u slučaju amina zaštićenih Boc-om s konačnih produkata skida zaštita u kiselim uvjetima.
A method for preparing a lyophilized pharmaceutical preparation according to any one of claims 1-3, whereby: melphalan flufenamide hydrochloride (J1) is dissolved in an organic solvent to obtain a melphalan flufenamide hydrochloride (J1) solution; 
Postupak za pripravu liofiliziranog farmaceutskog pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da: a. = melfenalan-flufenamid hidroklorid (ITI) se otopi u organskom otapalu kako bi se dobila otopina melfalan flufenamid hidroklorida (J1); b.
The methods according to this aspect of the invention comprise administering a therapeutically effective amount of a pharmaceutical composition comprising an angiopoietin or modified angiopoietin protein or a fragment thereof to a subject in need thereof. In certain embodiments, the at least one symptom, indication or complication is selected from the group consisting of fever, headache and myalgia followed by drowsiness, confusion, vascular leakage, loss of blood-brain barrier integrity, elevated blood level of an endothelial marker, sequestration of parasitized erythrocytes in the brain, impaired balance or coordination, motor impairment, splenomegaly, loss of reflexes and self-preservation, lack of hygiene-related behavior, acute lung injury, convulsion, coma and death. 
Pripravak za primjenu u metodi prema patentnom zahtjevu 1, naznačen time, što je najmanje jedan simptom, indikacija ili komplikacija odabrana iz grupe koja se sastoji od groznice, glavobolje i mijalgije popraćene pospanošću, konfuzijom, vaskularnim propuštanjem, gubitkom integriteta krvno-moždane barijere, povišenom razinom endotelnog markera u krvi, opcionalno odabrana iz grupe koja se sastoji od Angl, Ang2, Tie2, vWE, ICAM-1, E-selektina 1 VCAM-I, sekvestracije parazitiranih eritrocita u mozgu, narušene ravnoteže ili koordinacije, motoričkog oštećenja, splenomegalije, gubitka refleksa 1 samoodržanja, nedostatka higijene, akutne ozljede pluća, konvulzija, napadaja, kome i smrti.
the mature type I elastase protein is isolated by column chromatography, optionally wherein the chromatography includes cation exchange chromatography; and/or 
(a) zreli tip I elastaze proteina je izoliran kromatografijom na koloni, pri čemu opcionalno kromatografija uključuje kation izmenjivačku kromatografiju; i/ili
Reacting said aqueous suspension of succinylcasein obtained in step (a) with at least one iron salt to form ferro-succinylcasein, 
reakcije navedene vodene suspenzije sukcinilkazeina, dobivene u koraku (a), s najmanje jednom željeznom solju, kako bi se dobilo fero-sukcinilkazein,
The heterodimeric antibody of claim 3 or 4, wherein the CH3 domain of the first heavy chain further comprises a substitution, as compared to wildtype, of the amino acid residue at position 351 by a positively charged amino acid residue. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni prvi polipeptidni lanac koji sadrži CH3 domenu dalje sadrži ostatak lizina (K) na položaju amino-kiseline 351 u skladu s EU sustavom numeracije.
The dental post according to claim 1, wherein said post is further composed of a composite resin matrix comprising a dimethacrylate compound. The dental post according to claim 1, wherein a fraction of at least 40% and at most 80% in volume of the total content of said post is constituted by said fibers. 
Zubni most u skladu s najmanje jednim od patentnih zahtjeva 1 do 6, naznačen time što udio od najmanje 40% 1 najviše 80%, volumno, ukupnog sadržaja navedenog mosta čine navedena vlakna (8).
A second preferred pharmaceutical composition is the product of diluting the first preferred pharmaceutical composition into a D5W solution. 
Drugi pogodni farmaceutski sastav je proizvod razrjeđivanja prvog pogodnog farmaceutskog sastava u D5W otopini.
-[4-(Amino-cyclopropyl-methyl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one, and their stereoisomeric and/or tautomeric forms and/or their pharmaceutically acceptable salts thereof. 
-[4-(amino-ciklopropil-metil)-cikloheksiloksi]-7-kloro-2H-izokinolin-1-on, i njihovi stereoizomerni i/ili tautomerni oblici i/ili njihove farmaceutski prihvatljive soli.
administering to said patient a first buprenorphine-containing transdermal dosage form for a first dosing period that is no longer than about 5 days; 
(a) davanje navedenom pacijentu prvog transdermalnog oblika doziranja buprenorfina u prvom periodu doziranja koji ne traje duže od približno pet 5 dana;
A dose counter according to 6, wherein the gear wheel arranged for engagement by the second ratchet drive pawl is a second gear wheel coupled to the display, the second gear wheel having a circular arrangement of gear teeth. 
Brojač doza u skladu s patentnim zahtjevom 1, pri čemu je kotač sa zupčanikom koji je postavljen za pokretanje drugog pogona zapornog zaklopca (132) drugi kotač sa zupčanikom (130) povezan sa zaslonom, drugi kotač sa zupčanikom (130) ima kružno postavljene zupce zupčanika.
A compound of the Formula VI, VII, VIII, X or XX as defined in claim 37 or a salt thereof. 
Kemijski spoj, naznačen time da je prikazan Formulom VI, VII, VIII, X ili XX u skladu sa definicijom u zahtjevu 37, ili njegova sol.
said acid catalyst is preferably selected from the group consisting of mineral and organic acids. 
[image] gdje X se bira iz skupine koju čine S, O i NH.
In another embodiment, the protein of interest is recombinantly-produced rFVIII. BRIEF DESCRIPTION OF THE FIGURES 
Metoda iz patentnog zahtjeva 6 ili 7 pri čemu je protein od interesa rekombinantno proizvedeni rFVIII.
The antibody, conjugate or pharmaceutical composition for use according to claim 8, wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, cisplatin, taxotere, 5-fluoruracil, methotrexat, gemcitabin and cyclophosphamide. 
Protutijelo, konjugat ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 12, pri čemu je kemoterapijski agens odabran iz grupe koja se sastoji od doksorubicina, cisplatina, taksotere, 5-fluorouracila, metotreksata, gemcitabina i ciklofosfamida.
The mouse of claim 1, further comprising at an endogenous mouse B2 microglobulin locus a nucleotide sequence encoding a human or humanized B2 microglobulin polypeptide, wherein the mouse expresses the human or humanized B2 microglobulin polypeptide. 
Životinja prema zahtjevu 1, naznačena time, da nadalje na endogenom ne-humanom B2-mikroglobulin-lokusu, obuhvaća nukleotidnu sekvencu koja kodira humani ili humanizirani B2-mikroglobulin-polipeptid, pri čemu životinja izražava humani ili humanizirani B2-mikroglobulin-polipeptid.
2 c shows that the outer wall 16 is no longer in sealing contact with the peripheral part 13 of the base part 5 . 
Slika 2c prikazuje da vanjska stijenka 16 više nije u nepropusnom dodiru s rubnim dijelom 13 osnovnog dijela 5.
n = number of experiments 
Broj međunarodne objave:
wherein "alkenyl" means a linear or branched monovalent hydrocarbon radical of two to ten carbon atoms which has at least one double carbon-carbon bond, and which may be substituted with the same groups as alkyl. 
"alkenil" znači nerazgranati ili razgranati jednovalentni ugljikovodični radikal s 2 do 10 atoma ugljika, koji ima najmanje jednu dvostruku vezu ugljik-ugljik, te koji može biti supstituiran s istim skupinama kao alkil.
a communication device (146; 246) configured to allow a user to change and monitor the settings and/or state of the smoke inhalation device (100); 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je kućište (112) konfigurirana tako da korisniku omogućuje udisanje prve tvari i pri čemu prva tvar sadrži nikotin.
and R5 taken together with the nitrogen atom to which they are attached form a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, piperazine, morpholine, and 1,3-dihydro-isoindolyl, wherein said heterocyclic ring is optionally substituted one or more times with a substituent selected from the group consisting of methyl, ethyl, phenyl, N-acetyl and N-acetyl-methylamino; or a pharmaceutically acceptable salt thereof or an enantiomer or a diastereomer thereof. 
Ru i Rs, uzeti zajedno s atomom dušika na kojeg su vezani, tvore heterociklički prsten, kojeg se bira iz skupine koju čine pirolidin, piperidin, piperazin, morfolin, 1,3-dihidroizoindolil, gdje je navedeni heterociklički prsten izborno jednom ili višestruko supstituiran sa supstituentom kojeg se bira iz skupine koju čine metil, etil, fenil, N-acetil i N- acetilmetilamino; ili njegova farmaceutski prihvatljiva sol ili njegov enantiomer ili dijastereomer.
The reaction mixture was then stirred for 16 hours at room temperature, filtered and evaporated under vacuum to yield a crude 3,4-dihydro-l-dimethylamino-4-aryl- naphthalene solid. 
Reakcijska smjesa se tada miješa 16 sati na sobnoj temperaturi, filtrira se i ispari u vakuumu tako da se dobiva sirovi krut 3,4-dihidro-1-dimetilamino-4-arilnaftalin.
In particular embodiments, the antigen or antigenic peptide is from an organism selected from the group consisting of heartworm, e.g., canine heartworm Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplasma phagocytophilum, Anaplasma platys, feline leukemia virus, parvovirus, e.g., canine parvovirus, influenza A strain, influenza B strain, avian influenza virus, respiratory syncytial virus, Legionella, adenovirus, rotavirus, feline immunodeficiency virus, human immunodeficiency virus, and Group A Streptococcus. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što je navedeni antigen ili antigeni peptid iz organizma kojeg se bira iz skupine koju čine srčana glista, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplazma phagocytophilum, Anaplazma platys, virus mačje leukemije, parvovirus, soj A influence, soj B influence, virus ptičje influence, respiratorni sincicijski virus, Legionella, adenovirus, rotavirus, virus mačje imunodeficijencije, virus ljudske imunodeficijencije, te skupina A streptokoka.
The immunogenic composition of any one of paragraphs 62-73 wherein the same carrier protein is used in the Hib conjugate and two or more of the at least two further bacterial saccharide conjugates. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što isti proteinski nosač se upotrebljava u konjugatu Hib i u dva ili više od najmanje dva dodatna konjugata bakterijskih saharida.
The oligomer of claim 1, wherein the oligomer further comprises at least one of a modified internucleoside linkage and a modified nucleobase. 
Oligomer prema zahtjevu 1, naznačen time da oligomer nadalje sadrži barem jedno od modificirane internukleotide spojnice i modificirane nukleobaze.
-Q is pyrrolidinyl, wherein the point of attachment is via a ring carbon atom, and is substituted with “n” groups -J, and is substituted with “m” groups —RQ; or 
Q je pirolidinil, pri čemu je točka priključenja preko ugljikovog atoma u prstenu, i supstituiran je s "n" skupina –J, te je supstituiran s "m" skupina –RQ; ili
Polysorbate 60 or 80 affects the integrity of intestinal mucosa (Lieberman, H.A., Rieger, M.M. 
Polisorbat 60 ili 80 utječe na cjelovitost crijevne sluznice (Lieberman, H.A., Rieger, M.M, i Banker, G.S., Ur, Pharmaceutical Dosage Forms: Disperse Systems, 2.
in particular, unlike bacteria, may easily grow in an acid environment (see Vagi C, Taurus Pharma GmbH, Germany, Gebrauchsinformation). 
Posebice, za razliku od bakterija, mogu lako rasti u kiselom okolišu (vidi Vagi C, Taurus Pharma GmbH, Njemačka, Upute za upotrebu).